Data highlight high sensitivity of novel infrared spectroscopy approach for stage I disease
SCOTLAND, UK., March 29, 2022
Dxcover Limited, a clinical stage diagnostics company developing its spectroscopic liquid biopsy technology for early detection of multiple cancers, today announced that it will make four presentations at the 2022 American Association for Cancer Research(AACR) Annual Meetingtaking place in New Orleans,Louisiana from April 8-13, 2022. The e-posters will be made availableonline starting Friday, April 8 at 1:00pm ET.
“We are excited to present the validation of our technology for the early detection of brain cancer and to also highlight our ability to detect early-stage cancer, which has now been demonstrated in eight cancers including lung, colon, pancreatic, prostate, ovarian, breast, kidney, and brain. We look forward to progressing our clinical plans with leading clinicians in the USA and Europe,” said Dr Matthew J. Baker, Chief Technical Officer of Dxcover Limited.
Four abstracts (links below) have been accepted for presentation in the Clinical Prevention, Early Detection, and Interception (OPO.PR02.01) session at the conference, which showcase Dxcover’s ability to detect organ specific cancers earlier and perform multi-cancer combination tests:
